Clinical trial • Not applicable • Gastroenterology
Amoxicillin trihydrate; Potassium clavulanate for Perianal abscess | Anal fistula
Not applicable trial of Amoxicillin trihydrate; Potassium clavulanate for Perianal abscess | Anal fistula.
Overview
- Trial Therapeutic Area
- Gastroenterology
- Trial Disease
- Perianal abscess | Anal fistula
- Trial Stage
- Not applicable
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 21-12-2024
- First CTIS Authorization Date
- 14-01-2025
Trial design
Randomised, placebo (matching placebo); active treatment: amoxicillin/clavulanic acid viatris 875 mg/125 mg film-coated tablet, oral (product listed as investigational product).-controlled Not applicable trial across 1 site in Spain.
- Randomised
- Yes
- Comparator
- Placebo (matching placebo); Active treatment: Amoxicillin/clavulanic acid Viatris 875 mg/125 mg film-coated tablet, oral (product listed as investigational product).
- Target Sample Size
- 300
Eligibility
Recruits 300 Vulnerable population not selected. Inclusion requires signed written informed consent in accordance with ICH/GCP and local legislation obtained prior to any study procedure; 'Inability to give written informed consent' is listed as an exclusion criterion..
- Pregnancy Exclusion
- Women with positive pregnancy test result or breast-feeding.
- Vulnerable Population
- Vulnerable population not selected. Inclusion requires signed written informed consent in accordance with ICH/GCP and local legislation obtained prior to any study procedure; 'Inability to give written informed consent' is listed as an exclusion criterion.
Inclusion criteria
- {"criterion_text":"- Male or female adult patients of at least 18 years of age."}
- {"criterion_text":"- First episode of perianal abscess."}
- {"criterion_text":"- Oral feeding."}
- {"criterion_text":"- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures."}
- {"criterion_text":"- Signed written informed consent in accordance with ICH/GCP and local legislation, obtained prior to any study procedure."}
Exclusion criteria
- {"criterion_text":"- Allergy or intolerance to amoxicillin/clavulanic acid."}
- {"criterion_text":"- Contraindication to the performance of any of the study procedures."}
- {"criterion_text":"- History of previous perianal surgery."}
- {"criterion_text":"- Any clinical condition, and/or analytical alteration that, in the opinion of the investigator, is considered clinically significant enough to participate in the study. The following are considered as such: a)\tPrevious perianal fistula or fistula diagnosed during surgery. b)\tComplex abscess. c)\tMarked cellulitis after surgical drainage. d)\tHistory of inflammatory bowel disease. e)\tHistory of anal cancer. f)\tPrevious trauma or radiotherapy. g)\tDiabetes mellitus. h)\tImmunosuppressed: oncology patients, chronic corticosteroid treatment or other immunosuppressants, chronic kidney disease. i)\tProsthetic valves. j)\tMorbid obesity (BMI>40). k)\tSigns of severe sepsis"}
- {"criterion_text":"- Women with positive pregnancy test result or breast-feeding."}
- {"criterion_text":"- Unwillingness or inability to follow the procedures described in the protocol."}
- {"criterion_text":"- Inability to give written informed consent."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Percentage of patients who develop perianal fistula.","definition_or_measurement_approach":""}
Secondary endpoints
- {"endpoint_text":"- Time to onset of fistula (months).","definition_or_measurement_approach":"Time measured in months from index event to fistula onset."}
- {"endpoint_text":"- Complexity of the fistula according to the St James´s classification.","definition_or_measurement_approach":"Assessed according to the St James classification (imaging assessment referenced in translations)."}
- {"endpoint_text":"- Presence of new episode of perianal abscess at follow-up.","definition_or_measurement_approach":""}
- {"endpoint_text":"- Need for scheduled surgery for perianal fistula treatment (number of interventions, time since initial event and technique used).","definition_or_measurement_approach":"Captured as number of interventions, time since initial event and surgical technique used."}
- {"endpoint_text":"- Quality of life questionnaire after the onset of perianal fistula (QoLAF-Q questionnaire).","definition_or_measurement_approach":"Measured using the QoLAF-Q questionnaire."}
Recruitment
- Planned Sample Size
- 300
- Recruitment Window Months
- 69
- Consent Approach
- Signed written informed consent required from each participant prior to any study procedure, in accordance with ICH/GCP and local legislation. Subjects must be adults (≥18 years). A subject information and informed consent form document is listed for publication (patient information sheet). No assent process or additional languages explicitly stated in the record.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 300
Spain
- Earliest CTIS Part Ii Submission Date
- 13-01-2025
- Latest Decision Or Authorization Date
- 10-02-2026
- Processing Time Days
- 393
- Number Of Sites
- 1
- Number Of Participants
- 300
Sites
- Site Name
- Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda
- Department Name
- Cirugía General y del Aparato Digestivo
- Contact Person Name
- Verónica Polaino Moreno
- Contact Person Email
- fneira@idiphim.org
Sponsor
Primary sponsor
- Full Name
- MARIANO ARTES CASELLES
- Organisation Type
- Health care
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- Amoxicilina/Ácido clavulánico Viatris 875 mg/125 mg comprimidos recubiertos con película EFG
- Active Substance
- Amoxicillin trihydrate; Potassium clavulanate
- Modality
- Small molecule
- Routes Of Administration
- Oral
- Route
- Oral
- Authorisation Status
- Authorised (marketing authorisation in Spain, marketingAuthNumber 64712)
- Starting Dose
- 875 mg/125 mg (tablet)
- Dose Levels
- 875 mg/125 mg
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.